NCT03164629 is a NA clinical trial of cone-beam CT 3D Emboguide in Enlarged Prostate, sponsored by University of Miami.

Who is sponsoring NCT03164629?

NCT03164629 is sponsored by University of Miami.

What drugs are being tested in NCT03164629?

Interventions in NCT03164629: cone-beam CT 3D Emboguide.

What condition does NCT03164629 study?

NCT03164629 studies Enlarged Prostate.

Is NCT03164629 still recruiting?

NCT03164629 is currently completed. Last updated 11 June 2019.

Are results published for NCT03164629?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-06-11 · How we verify

NCT03164629

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

3D Rotational CT Angiogram With Embolization Guidance and CBCT in Prostatic Artery Embolization

Completed NA Results posted Last updated 11 June 2019

What this trial tests

NA trial testing cone-beam CT 3D Emboguide in Enlarged Prostate in 50 participants. Completed in 19 October 2018.

Timeline

17 April 2017

Primary endpoint
19 October 2018

19 October 2018

Quick facts

Lead sponsor	University of Miami
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	50
Start date	17 April 2017
Primary completion	19 October 2018
Estimated completion	19 October 2018
Sites	1 location across United States

Drugs / interventions tested

cone-beam CT 3D Emboguide

Conditions studied

Enlarged Prostate — all drugs for Enlarged Prostate →

Sponsor

University of Miami

Who can join

Adults 50 to 79, male only, with Enlarged Prostate. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Time for Prostatic Artery Catheterization Primary · hour 2

For the cases using Emboguide this will be measured as the time from which the Emboguide is displayed on the live fluoroscopy to the time of prostatic artery catheterization. Emboguide display is in addition to the angiogram roadmap display. For the control cases this will be measured as the time from which the angiogram is displayed on the live fluoroscopy to the time of prostatic artery catheterization.

Right Artery

Group	Value	95% CI
3D Angiogram + Emboguide	273.40	± 406.64
No 3D Angiogram + Emboguide	181.71	± 185.11

Left Artery

Group	Value	95% CI
3D Angiogram + Emboguide	206.38	± 228.96
No 3D Angiogram + Emboguide	155.96	± 216.32

Sponsor's own description

The purpose of this research study is to learn about how cone-beam Computerized Tomography scans (X-ray images taken from different angles) work together with an embolization guidance software (helps the doctor see the arteries that feed the prostate)to find and see arteries in the prostate.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University of Miami trials

Trials by the same sponsor.

NCT06003712 — Exploring the Effect of Mindfulness on Quality of Life (QoL) in Spinal Cord Injury (SCI) · NA · not yet recruiting
NCT06077071 — MRIdian "RADAR" Trial · NA · not yet recruiting
NCT07472413 — Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project · Phase 3 · not yet recruiting
NCT07322289 — Antibiotic-coated Braided Suture Study · NA · not yet recruiting
NCT07469592 — eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03164629 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Miami
Last refreshed: 11 June 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03164629.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing